First Trust NYSE Arca Biotechnology Index Fund (FBT)

138.89
Delayed Data
As of Jul 01
 +3.33 / +2.46%
Today’s Change
121.68
Today|||52-Week Range
176.07
-14.24%
Year-to-Date

Investment Objective

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.

No recent news for First Trust NYSE Arca Biotechnology Index Fund.

Performance

1 month+4.17% 3 years-0.10%
3 months-9.42% 5 years+4.34%
1 year-19.03% Since inception+13.05%
Data through 07/02/2022

Quote Details

Previous close$135.56
Open day’s range136.87 – 139.02
Net asset value (NAV)139.03 (07/01/2022)
Daily volume101,481
Average volume (3 months)43,989
Data as of 3:59pm ET, 07/01/2022

Peer Comparisonvs. Health ETFs

 FBTCategory
Performance 5-yr return+4.34%+11.31%
Expense Gross exp ratio0.55%1.01%
Risk 5 year sharpe ratio0.300.52
Net assets$1.3B$1.9B
Average market cap$14.2B$43.0B
Average P/E15.422.2
Dividend / Share--0.27%

Competitors

VHT Vanguard Health Care Index Fund ETF Shar...
IEHS iShares Evolved U.S. Healthcare Staples ...
FHLC Fidelity MSCI Health Care Index ETF

Holdings

Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
UTHR United Therapeutics Corp4.55%
GRFS Grifols SA4.54%
GILD Gilead Sciences3.97%
ALKS Alkermes Plc3.87%
AMGN Amgen3.82%
-- 3.72%
MTD Mettler-Toledo International Inc3.67%
NBIX Neurocrine Biosciences Inc3.57%
BIIB Biogen3.55%
VRTX Vertex Pharmaceuticals Inc3.53%